Hikma Pharmaceuticals PLC (HIK)

1,655.50
+17.00(+1.04%)
  • Volume:
    343,551
  • Bid/Ask:
    1,195.00/1,710.00
  • Day's Range:
    1,637.50 - 1,680.00

HIK Overview

Prev. Close
1,638.5
Day's Range
1,637.5-1,680
Revenue
1.01B
Open
1,637.5
52 wk Range
1,174.5-2,137
EPS
1.51
Volume
343,551
Market Cap
3.66B
Dividend (Yield)
0.55
(2.61%)
Average Volume (3m)
536,139
P/E Ratio
12.51
Beta
0.266
1-Year Change
-18.29%
Shares Outstanding
220,235,852
Next Earnings Date
23 Feb 2023
What is your sentiment on Hikma Pharma?
or
Market is currently closed. Voting is open during market hours.

Hikma Pharmaceuticals PLC News

Hikma Pharmaceuticals PLC Analysis

Hikma Pharmaceuticals PLC Company Profile

Hikma Pharmaceuticals PLC Company Profile

Employees
8700

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates through three segments, such as Injectables, Generics and Branded. The Injectables business develops and manufactures generic injectable products, which are primarily used in hospitals. The Generics business develops and manufactures oral and other non-injectable generic products. The Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in Middle East/North Africa (MENA). The Company’s products are sold in the retail and hospital markets. It also markets its products in Canada, which includes approximately 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellNeutralNeutral
Technical IndicatorsStrong SellStrong SellBuyStrong SellStrong Sell
SummaryStrong SellStrong SellNeutralSellSell
  • I am working
    0
    • hi
      0
      • Touch 27 today
        0
        • Next results will be super. Wait for it to hit £32 before end of this year
          0
          • Aim listed Dark Matter Ltd, has more potential
            2
            • This will go up & up
              1
              • Not as stated here (March 11)
                1
                • Hikma will announce their results for the year ended 31 December 2019 on 27 February 2020
                  0
                  • Any hint of progress on Advair will send this stock much higher still !
                    0
                    • Underpriced without the Advair approvals ' unfortunate about the 2019 target for Advair !!!
                      0